C3 deposition glomerulopathy due to a functional factor H defect.

[1]  H. Cook,et al.  Translational Mini‐Review Series on Complement Factor H: Renal diseases associated with complement factor H: novel insights from humans and animals , 2008, Clinical and experimental immunology.

[2]  U. Schlötzer-Schrehardt,et al.  MPGN II – genetically determined by defective complement regulation? , 2007, Pediatric Nephrology.

[3]  R. Salomon,et al.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome , 2006, Journal of Medical Genetics.

[4]  P. Zipfel,et al.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). , 2006, Kidney international.

[5]  J L McRae,et al.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease) , 2005, Journal of Medical Genetics.

[6]  John D Lambris,et al.  Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. , 2005, Journal of the American Society of Nephrology : JASN.

[7]  P. Zipfel,et al.  Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  N. Gretz,et al.  Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long‐term follow‐up , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[9]  S. Meri,et al.  Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. , 1999, Journal of immunology.

[10]  H. Rennke.  Secondary membranoproliferative glomerulonephritis. , 1995, Kidney international.

[11]  S. Meri,et al.  Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis , 1992, The Journal of experimental medicine.

[12]  D. Fearon,et al.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. , 1976, Journal of immunology.

[13]  P. Zipfel,et al.  Complement and diseases: defective alternative pathway control results in kidney and eye diseases. , 2006, Molecular immunology.

[14]  M. Oppermann,et al.  Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. , 2004, Histology and histopathology.

[15]  Matthias Kretzler,et al.  Cell biology of the glomerular podocyte. , 2003, Physiological reviews.